

<b>Report Title</b>	Integrated Quality & Performance Report - February 2020		
<b>Sponsoring Executive</b>	Dave Baker (Director of Partnerships and Innovation)		
<b>Report Author</b>	Yasmina Gainer, Head of Performance and Costing		
<b>Meeting</b>	Trust Board (Public)	<b>Date</b>	2 April 2020

### 1. Suggested discussion points *[two or three issues you consider the Board should focus on]*

February performance appears largely unaffected by COVID-19, however, March is likely to be more challenging. The focus will be to try to maintain current performance where possible.

- Cancer 62-day standard has not delivered in January and February. It is anticipated that we will miss Q4 delivery; the main reason is the Gynae cancer pathway.
- 1x Serious Medication error has been recorded in February and 1x Serious Injury due to falls. Both will report out to the Executive Quality Committee when investigations are complete. February continues however to show a stable, low falls rate overall.
- Whilst sickness is at 5% in month the long term sickness cases are down to 114 against the 140 target.
- Mandatory training (staff at 100% compliance) at 71.5% with a big effort planned in March to achieve the 95% although this will be more challenging without face to face training.
- Whilst Neutropenic sepsis performance has continued to improve 3 of the 11 breaches in month were well above the 1 hour target. 2 of these had clinical reasons for the time period. Performance in March for Neutropenic Sepsis looks strong at present.
- The CQC Use of resources tab has been added and will become increasingly populated. Next month we plan to propose targets against each metric within it to the PMC.

### 2. Alignment to 2020 Vision *[indicate with an 'X' which Plan this paper supports]*

Safety Plan	X	Public Health Plan	X	People Plan & Education Plan	X
Quality Plan	X	Research and Development		Estates Plan	
Financial Plan		Digital Plan		Other <i>[specify in the paper]</i>	

### 3. Previous consideration *[where has this paper been previously discussed?]*

WD5 Distribution to Groups, OMC, PMC, Q&S

### 4. Recommendation(s)

The Trust Board is asked to:

- Note the February 2020 performance highlights and potential risks to performance from COVID-19
- Note the persistent red performance

### 5. Impact *[indicate with an 'X' which governance initiatives this matter relates to and where shown elaborate]*

Trust Risk Register	X	Numerous				
Board Assurance Framework	X	SBAF 11: Labour Supply and SBAF 14: Amenable Mortality				
Equality Impact Assessment	Is this required?	Y		N	x	If 'Y' date completed
Quality Impact Assessment	Is this required?	Y		N	x	If 'Y' date completed